Platinum Compounds and Sodium Metabolism in Children with Diencephalic Glioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2013 Jul 11

PMID 23839227

Authors

N Puma

A Ruggiero

M Scalzone

P Coccia

S Triarico

G Trombatore

S Mastrangelo

R Riccardi

Affiliations

Soon will be listed here.

Abstract

In this brief report we have described eight children affected by optic pathway/hypothalamus gliomas and treated with carboplatin and/or cisplatin, which developed a derangement of sodium and water metabolism, due to diabetes insipidus (DI) or to syndrome of inappropriate antidiuretic hormone secretion (SIADH) after surgical resection. In four out of these eight patients the treatment with platinum compounds produced prolonged haematological toxicity and in five out of them it caused neurosensorial bilateral hypoacusia. In addition cisplatin worsened electrolytes disturbances. Hence children with DI or SIADH should be carefully monitored before, during and after the treatment with platinum compounds.

References

Skinner R, Parry A, Price L, Cole M, Craft A, Pearson A . Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer. 2009; 45(18):3213-9. DOI: 10.1016/j.ejca.2009.06.032. View

Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P . Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010; 125(4):e938-50. PMC: 3106205. DOI: 10.1542/peds.2009-1597. View

Afzal S, Wherrett D, Bartels U, Tabori U, Huang A, Stephens D . Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. J Neurooncol. 2009; 97(3):393-9. DOI: 10.1007/s11060-009-0033-z. View

Buonocore C, Robinson A . The diagnosis and management of diabetes insipidus during medical emergencies. Endocrinol Metab Clin North Am. 1993; 22(2):411-23. View

ODwyer P, Stevenson J, Johnson S . Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000; 59 Suppl 4:19-27. DOI: 10.2165/00003495-200059004-00003. View

Packer R, Ater J, Allen J, Phillips P, Geyer R, Nicholson H . Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997; 86(5):747-54. DOI: 10.3171/jns.1997.86.5.0747. View

Kim S, Lee J, Kang D, Ahn K, Lee H, Choi K . Cisplatin decreases the abundance of aquaporin water channels in rat kidney. J Am Soc Nephrol. 2001; 12(5):875-882. DOI: 10.1681/ASN.V125875. View

Fisher B, Leighton C, Vujovic O, Macdonald D, Stitt L . Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys. 2001; 51(3):704-10. DOI: 10.1016/s0360-3016(01)01705-9. View

Yao X, Panichpisal K, Kurtzman N, Nugent K . Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007; 334(2):115-24. DOI: 10.1097/MAJ.0b013e31812dfe1e. View

10.

Bryant W, OMarcaigh A, Ledger G, Zimmerman D . Aqueous vasopressin infusion during chemotherapy in patients with diabetes insipidus. Cancer. 1994; 74(9):2589-92. DOI: 10.1002/1097-0142(19941101)74:9<2589::aid-cncr2820740929>3.0.co;2-6. View

11.

Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1999; 34(10):1522-34. DOI: 10.1016/s0959-8049(98)00224-x. View

12.

Ross C, Katzov-Eckert H, Dube M, Brooks B, Rassekh S, Barhdadi A . Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009; 41(12):1345-9. DOI: 10.1038/ng.478. View

13.

Kellie S, Boyce H, Dunkel I, Diez B, Rosenblum M, Brualdi L . Intensive cisplatin and cyclophosphamide-based chemotherapy without radiotherapy for intracranial germinomas: failure of a primary chemotherapy approach. Pediatr Blood Cancer. 2004; 43(2):126-33. DOI: 10.1002/pbc.20026. View

14.

Willox J, McAllister E, Sangster G, Kaye S . Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer. 1986; 54(1):19-23. PMC: 2001660. DOI: 10.1038/bjc.1986.147. View

15.

Kovacs L, Robertson G . Syndrome of inappropriate antidiuresis. Endocrinol Metab Clin North Am. 1992; 21(4):859-75. View

16.

Bertolini P, Lassalle M, Mercier G, Raquin M, Izzi G, Corradini N . Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss. J Pediatr Hematol Oncol. 2004; 26(10):649-655. DOI: 10.1097/01.mph.0000141348.62532.73. View

17.

Launay-Vacher V, Rey J, Isnard-Bagnis C, Deray G, Daouphars M . Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008; 61(6):903-9. DOI: 10.1007/s00280-008-0711-0. View

18.

Jones D, Spunt S, Green D, Springate J . Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 51(6):724-31. PMC: 2734519. DOI: 10.1002/pbc.21695. View

19.

Binning M, Liu J, Kestle J, Brockmeyer D, Walker M . Optic pathway gliomas: a review. Neurosurg Focus. 2007; 23(5):E2. DOI: 10.3171/FOC-07/11/E2. View